Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia

10 Aug 2011

Abstract excerpt

Low MN1 expression bestows favorable prognosis in younger adults with cytogenetically normal acute myeloid leukemia (CN-AML), but its prognostic significance in older patients is unknown. We analyzed pretherapy MN1 expression in 140 older (≥ 60 years) de novo CN-AML patients treated on cytarabine/daunorubicin-based protocols. Low MN1 expressers had higher complete remission (CR) rates (P = .001), and longer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21828125
DOI: 10.1182/blood-2011-06-357764

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemiaPMID 21828125Read ↗

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.Semantic proximity Read ↗

Refinement of Risk-Stratification of Cytogenetically Normal Acute Myeloid Leukemia Adult Patients by MN1 Expression.Semantic proximity Read ↗

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.Semantic proximity Read ↗

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.Semantic proximity Read ↗

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies.Semantic proximity Read ↗

Mutational spectrum of de novo NPM1-mutated acute myeloid leukemia patients older than 75 years.Semantic proximity Read ↗

Acute Myeloid Leukaemia with Normal Cytogenetics and NPM1-Mutation: Impact of Mutation Topography on OutcomesSemantic proximity Read ↗

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.Semantic proximity Read ↗

High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemiaSemantic proximity Read ↗

Genomic structural variations contribute to inform prognosis in patients with cytogenetically normal acute myeloid leukemia.Semantic proximity Read ↗

Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome predictionSemantic proximity Read ↗

NPM1-Mutated Acute Myeloid Leukemia: Recent Developments and Open Questions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.